Evaluation of long-acting injectable antipsychotics with the corresponding oral formulation in a cohort of patients with schizophrenia: a real-world study in Spain
In conclusion, LAIs improved clinical outcomes by reducing the need for concomitant treatments and hospital admissions over oral antipsychotics. PP1M and PP3M showed better outcomes versus A1M and biweekly LAIs. (Source: International Clinical Psychopharmacology)
Source: International Clinical Psychopharmacology - November 26, 2020 Category: Psychiatry Tags: Original Articles Source Type: research

Abnormally low prolactin levels in schizophrenia patients after switching to aripiprazole in a randomized trial: a biomarker for rebound in psychotic symptoms?
This study aimed to assess whether the aripiprazole-i... (Source: BMC Psychiatry)
Source: BMC Psychiatry - November 23, 2020 Category: Psychiatry Authors: Ya-Wen Jen, Tzung-Jeng Hwang, Hung-Yu Chan, Ming H. Hsieh, Chen-Chung Liu, Chih-Min Liu, Hai-Gwo Hwu, Ching-Hua Kuo, Yi-Ting Lin, Yi-Ling Chien and Wei J. Chen Tags: Research article Source Type: research

[Tardive dyskinesia in a child treated with atypical antipsychotics].
We describe the case of a 12-year-old boy that developed invalidating motor symptoms after starting and gradually increasing the dose of quetiapine with extended release and phasing out aripiprazole. The symptoms met the definition of tardive dyskinesia given their duration and presentation. Symptoms decreased spontaneously after discontinuation of neuroleptic treatment. The literature and knowledge among clinicians concerning the occurrence of tardive dyskinesia in children and adolescents treated with atypical antipsychotics are limited. We give an overview of the available scientific findings with special attention to t...
Source: Tijdschrift voor Psychiatrie - November 17, 2020 Category: Psychiatry Authors: Wittevrongel E, Vranken E, Pepermans A, Jaspers T Tags: Tijdschr Psychiatr Source Type: research

Amisulpride Found More Effective Than Olanzapine or Aripiprazole
This study is interesting in that it was designed pragmatically to be more generalizable to the broader clinical population, yet it still produced dramatic results,” Stephen Marder, M.D., a professor of psychiatry and biobehavioral sciences at the University of California, Los Angeles, told Psychiatric News. Marder, who was not involved with the study, noted that the differences in PANSS scores between amisulpride and the other drugs corresponded to effect sizes of over 0.5 —significant changes that a physician would notice quickly. “I’m hopeful that studies like this may encourage industries to spo...
Source: Psychiatr News - November 16, 2020 Category: Psychiatry Tags: amisulpride antipsychotics aripiprazole Lancet Psychiatry negative symptoms olanzapine PANSS positive symptoms schizophrenia Source Type: research

Sex-Specific Associations Between Bipolar Disorder Pharmacological Maintenance Therapies and Inpatient Rehospitalizations: A 9-Year Swedish National Registry Study
Conclusion: The effectiveness of most maintenance therapies is generally comparable and uniform among both males and females. Despite some statistically significant sex-specific associations, estimates for each drug were fairly consistent between sexes. (Source: Frontiers in Psychiatry)
Source: Frontiers in Psychiatry - November 12, 2020 Category: Psychiatry Source Type: research

Slim and Euthymic Tamoxifen and Aripiprazole in Bipolar Disorder: A Case Report
No abstract available (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - November 1, 2020 Category: Psychiatry Tags: Letters to the Editors — Case Reports Source Type: research

Identification of a Set of Patient-Related Features to Foster Safe Prescribing of Specific Antipsychotics in the Elderly With Dementia
Conclusions: Even though a high number of PRFs were rated as clinically relevant, some of them were identified as frequently missing from medical records. This may suggest that medical records should be complemented with other sources (e.g., nursing and pharmacy records) to ensure a safe prescribing of APs. (Source: Frontiers in Psychiatry)
Source: Frontiers in Psychiatry - October 30, 2020 Category: Psychiatry Source Type: research

A safety evaluation of aripiprazole in the treatment of schizophrenia.
Authors: Preda A, Shapiro BB Abstract INTRODUCTION: Aripiprazole is a third generation antipsychotic approved by the US Food and Drug Administration (FDA) for the treatment of schizophrenia. Aripiprazole is available as oral and long-acting injectable (LAI) depot formulations, with a unique mechanism of action comprising partial D2 and serotonin 5-HT1A agonism and antagonism at serotonin 5-HT2A receptors. AREAS COVERED: We review short-and-long-term clinical trials, meta-analyses of clinical trials and product information pertaining to the safety and efficacy of aripiprazole in adults with schizophren...
Source: Expert Opinion on Drug Safety - October 20, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research

Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial
Publication date: November 2020Source: The Lancet Psychiatry, Volume 7, Issue 11Author(s): Erik Johnsen, Rune A Kroken, Else-Marie Løberg, Maria Rettenbacher, Inge Joa, Tor Ketil Larsen, Solveig Klæbo Reitan, Berit Walla, Renata Alisauskiene, Liss Gøril Anda, Christoffer Bartz-Johannessen, Jan Øystein Berle, Jill Bjarke, Farivar Fathian, Kenneth Hugdahl, Eirik Kjelby, Igne Sinkeviciute, Silje Skrede, Lena Stabell, Vidar M Steen (Source: The Lancet Psychiatry)
Source: The Lancet Psychiatry - October 16, 2020 Category: Psychiatry Source Type: research

Recurrence rates in stable bipolar disorder patients after drug discontinuation v. drug maintenance: a systematic review and meta-analysis.
CONCLUSIONS: Maintaining drug treatment during clinically stable BD prevented recurrence for up to 24 months. Discontinuation of medications for ⩾1 month significantly increased recurrence risk. However, 47.3% of patients who discontinued drugs for 6 months did not experience recurrence. PMID: 33046156 [PubMed - as supplied by publisher] (Source: Psychological Medicine)
Source: Psychological Medicine - October 13, 2020 Category: Psychiatry Authors: Kishi T, Matsuda Y, Sakuma K, Okuya M, Mishima K, Iwata N Tags: Psychol Med Source Type: research

The effectiveness of very slow switching to aripiprazole in schizophrenia patients with dopamine supersensitivity psychosis: a case series from an open study
This study was a single-armed and open-labeled study in which patients were observed over a period of 2 years. Only 11 patients were ultimately recruited. Five patients were successfully switched to a sufficient dose of aripiprazole and completed the study protocol. These five patients did not present with severe DSP over the study period, but only one patient showed a large improvement in psychopathology. Five patients dropped out of the study, and one of these five showed a severe worsening of psychosis. The present study indicated that the introduction of aripiprazole in patients with DSP was difficult, but sugge...
Source: International Clinical Psychopharmacology - October 4, 2020 Category: Psychiatry Tags: Original Articles Source Type: research

A Mixed Presentation of Serotonin Syndrome vs Neuroleptic Malignant Syndrome in a 12-Year-Old Boy
Conclusion The use of antipsychotic medications for young children with behavioral problems has risen dramatically in the last decade, increasing their risk for developing SS or NMS. (Source: Pediatric Emergency Care)
Source: Pediatric Emergency Care - October 1, 2020 Category: Emergency Medicine Tags: Illustrative Cases Source Type: research

24.1 the nordic long-term ocd treatment study (nordlots): design, methods, and immediate outcomes
The aim of this presentation is to describe and discuss the methodology of the Nordic Long-Term OCD Treatment Study (NordLOTS) and to summarize results from its first step. The study ’s purpose was to evaluate treatment outcome of CBT, to identify CBT nonresponders or partial responders, and to investigate whether an increased number of CBT sessions or sertraline treatment gives the best outcome. Additionally, the aim of this presentation is to identify treatment-refractory pa tients and to investigate the outcome of aripiprazole augmentation when other strategies proved inadequate. (Source: Journal of the American A...
Source: Journal of the American Academy of Child and Adolescent Psychiatry - October 1, 2020 Category: Psychiatry Authors: Per Hove Thomsen, Tord Ivarsson, Nor C. Torp, Kitty Dahl, Robert Valderhaug, Bernhard Weidle, Judith Nissen, Karin A. Melin, Gudmundur Skarphedinsson, Katja A. Hybel Tags: Symposium 24 Source Type: research

Little Agreement on Treating Residual Bipolar Disorder Symptoms in a Child.
Conclusions: There was wide variation in suggestions on to how to treat persistent symptoms of anxiety, ADHD, and oppositional behavior in a child whose mania and depression had been brought under good control. We surmise that this great diversity in recommendations among experts in child and adult bipolar disorder stems at least partially from inadequate literature on treatment and that a new emphasis on funding and conducting studies on efficacy and effectiveness is needed. PMID: 32942345 [PubMed - as supplied by publisher] (Source: The Primary Care Companion for CNS Disorders)
Source: The Primary Care Companion for CNS Disorders - September 18, 2020 Category: Primary Care Tags: Prim Care Companion CNS Disord Source Type: research

Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics
AbstractFasting hyperglycemia, impaired glucose tolerance, prediabetes, and diabetes are frequently present in patients treated with second-generation antipsychotics (SGAPs) for schizophrenia, bipolar disorder, and other severe mental illnesses. These drugs are known to produce weight gain, which may lead to insulin resistance, glucose intolerance, and metabolic syndrome, which constitute important risk factors for the emergence of diabetes. The aim of this review was to formulate therapeutic guidelines for the management of diabetes in patients treated with SGAPs, based on the association between SGAP-induced weight gain ...
Source: Drugs - September 14, 2020 Category: Drugs & Pharmacology Source Type: research

Novel Pharmacological Approaches for Tourette Syndrome
AbstractPurpose of the ReviewThe need to develop novel pharmacological approaches for TS is balanced by the necessity for interventions to be safe and tolerable. This review provides an overview of studies of medications for TS over the last 3  years.Recent FindingsFour studies of deutetrabenazine and valbenazine in TS failed in their primary outcomes. Ecopipam was more effective than placebo in reducing tics in children. Preliminary evidence suggests that a new endocannabinoid modulator (ABX-1431) has an acute effect on tics in adults. Intravenous valproic acid was more effective than oral aripiprazole in children wi...
Source: Current Developmental Disorders Reports - September 14, 2020 Category: Child Development Source Type: research

Aripiprazole in Children and Adolescents
Journal of Child and Adolescent Psychopharmacology, Ahead of Print. (Source: Journal of Child and Adolescent Psychopharmacology)
Source: Journal of Child and Adolescent Psychopharmacology - September 14, 2020 Category: Pediatrics Authors: Nicolas Coustals Marie-Line M énard David Cohen Source Type: research

Safety and tolerability of antipsychotic agents in neurodevelopmental disorders: a systematic review.
Authors: Iasevoli F, Barone A, Buonaguro EF, Vellucci L, de Bartolomeis A Abstract INTRODUCTION: Neurodevelopmental disorders (NDDs) are a group of complex and heterogeneous disorders, caused by the disruption of normal brain development. Antipsychotic agents are frequently used in these disorders to treat maladaptive conduct. However, a systematic evaluation of their safety/tolerability in NDDs is still lacking. Given the unique neurobiology of NDDs, antipsychotics may be expected to elicit distinctive side effects. AREAS COVERED: PubMed was systematically searched for all published studies from 1980 until 202...
Source: Expert Opinion on Drug Safety - September 9, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research

Is aripiprazole a key to unlock anorexia nervosa?: A case series
Aripiprazole contributes an increase in body mass index and attenuation in anorexia nervosa (AN) symptoms, leading clinical improvements with lower side ‐effect profile; but it is not enough to cure comorbid depressive symptoms in AN. AbstractAripiprazole contributes an increase in body mass index and attenuation in anorexia nervosa (AN) symptoms, leading clinical improvements with lower side ‐effect profile; but it is not enough to cure comorbid depressive symptoms in AN. (Source: Clinical Case Reports)
Source: Clinical Case Reports - September 5, 2020 Category: General Medicine Authors: Ak ın Tahıllıoğlu, Tuğçe Özcan, Gamze Yüksel, Noorjahan Majroh, Sezen Köse, Burcu Özbaran Tags: CASE REPORT Source Type: research

Low-oxidation-potential thiophene-carbazole monomers for electro-oxidative molecular imprinting: Selective chemosensing of aripiprazole
Publication date: Available online 3 September 2020Source: Biosensors and BioelectronicsAuthor(s): Marianna Gajda, Renata Rybakiewicz, Maciej Cieplak, Teresa Żołek, Dorota Maciejewska, Edyta Gilant, Piotr J. Rudzki, Katarzyna Grab, Andrzej Kutner, Paweł Borowicz, Wlodzimierz Kutner, Krzysztof R. Noworyta (Source: Biosensors and Bioelectronics)
Source: Biosensors and Bioelectronics - September 4, 2020 Category: Biotechnology Source Type: research

One Plus One Sometimes Equals More Than Two: Long-acting Injectable Aripiprazole Adjunction in Clozapine-Resistant Schizophrenia
In this report, we present a patient whose positive symptoms did not improve despite being treated with clozapine monotherapy at a therapeutic dose for 4 months, and whose symptoms began to resolve after aripiprazole long-acting injection adjunction to clozapine. A 22-year-old man was diagnosed as having schizophrenia last year in his first admission, with symptoms of auditory hallucinations, persecutory delusions, and associated social withdrawal. His positive symptoms did not improve despite being treated with risperidone, olanzapine, and paliperidone. Oral clozapine monotherapy was planned, and the daily dose was increa...
Source: Clinical Neuropharmacology - September 1, 2020 Category: Neurology Tags: Case Reports Source Type: research

Aripiprazole-Induced Urinary Incontinence.
Authors: Uvais NA, Mohammed TP PMID: 32857928 [PubMed - as supplied by publisher] (Source: The Primary Care Companion for CNS Disorders)
Source: The Primary Care Companion for CNS Disorders - August 29, 2020 Category: Primary Care Tags: Prim Care Companion CNS Disord Source Type: research

Beyond 52-Week Long-Term Safety: Long-Term Outcomes of Aripiprazole Lauroxil for Patients With Schizophrenia Continuing in an Extension Study.
Authors: Lauriello J, Claxton A, Du Y, Weiden PJ Abstract OBJECTIVE: To describe the long-term safety, tolerability, and symptom trajectory with the long-acting injectable antipsychotic aripiprazole lauroxil (AL) in patients with DSM-5-diagnosed schizophrenia followed for up to 180 weeks (3.5 years). METHODS: Long-term safety of 2 fixed doses of AL (441 or 882 mg every 4 weeks) was assessed during up to 180 weeks (3.5 years) of continuous AL exposure using data from 2 sequential long-term safety studies. Safety metrics included adverse events (AEs), AEs leading to study discontinuations, physical examinations, ...
Source: Journal of Clinical Psychiatry - August 27, 2020 Category: Psychiatry Tags: J Clin Psychiatry Source Type: research

Current Management of Tics and Tourette Syndrome: Behavioral, Pharmacologic, and Surgical Treatments
AbstractTourette syndrome is a heterogeneous neurobehavioral disorder manifested by childhood-onset motor and phonic tics, often accompanied by a variety of behavioral comorbidities, including attention deficit and obsessive compulsive disorder. Treatment must be tailored to the needs and goals of the individual patients and their families. All patients should receive education on the condition and, if possible, engage behavioral therapy targeted towards tics and/or comorbidities. Pharmacological therapies, such as alpha agonists, topiramate, and vesicular monoamine transport type 2 inhibitors, are generally used as first-...
Source: Neurotherapeutics - August 26, 2020 Category: Neurology Source Type: research

CYP2D6 Phenotype Influences Aripiprazole Tolerability in Pediatric Patients with Mood Disorders
Journal of Child and Adolescent Psychopharmacology, Ahead of Print. (Source: Journal of Child and Adolescent Psychopharmacology)
Source: Journal of Child and Adolescent Psychopharmacology - August 24, 2020 Category: Pediatrics Authors: Sahar A. Jallaq Mark Verba Jeffrey R. Strawn Lisa J. Martin Melissa P. DelBello Laura B. Ramsey Source Type: research

Risk factors and pattern of weight gain in youths using antipsychotic drugs
AbstractAntipsychotic-induced weight gain is a major health concern in children and adolescents. The aim of this study was to identify risk factors for weight gain during short-, middle- and long-term treatment with antipsychotic drugs in this young population. We analysed a combined prospective and a retrospective observational cohort of Dutch children and adolescents, starting with risperidone, aripiprazole or pipamperone treatment. Linear mixed models were used to test whether sex, age, baseline body-mass-index (BMI)zscore, type of antipsychotic, dose equivalent/kg, duration of use, previous antipsychotic use, ethnicity...
Source: European Child and Adolescent Psychiatry - August 23, 2020 Category: Psychiatry Source Type: research

Psychomotor agitation and hyperactive delirium in COVID-19 patients treated with aripiprazole 9.75 mg/1.3 ml immediate release
(Source: Psychopharmacology)
Source: Psychopharmacology - August 20, 2020 Category: Psychiatry Source Type: research

Clozapine Found Most Likely of Common Antipsychotics to Reduce Risk of Suicide in Patients With Schizophrenia
Compared with other common antipsychotics, clozapine appears most likely to decrease the risk of suicidal outcomes in patients with schizophrenia, according to areport inSchizophrenia Bulletin.The findings were based on two nationwide register-based cohort studies of 61,889 patients with schizophrenia who lived in Finland and 29,823 patients with schizophrenia who lived in Sweden. Heidi Taipale, Ph.D., of the University of Eastern Finland and colleagues specifically focused on patients who took the following first- or second-generation antipsychotics: clozapine, olanzapine, quetiapine, risperidone, risperidone (long-acting...
Source: Psychiatr News - August 18, 2020 Category: Psychiatry Tags: antipsychotics benzodiazepines clozapine schizophrenia suicide suicide attempt suicide death Source Type: research

Aripiprazole prevents from development of vincristine-induced neuropathic nociception by limiting neural NOS overexpression and NF-kB hyperactivation
ConclusionIn conclusion, aripiprazole effectively prevents from vincristine-induced neuropathy by limiting nNOS overexpression and NF-kB hyperactivation. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - August 13, 2020 Category: Cancer & Oncology Source Type: research

Cost-effectiveness of aripiprazole orally disintegrating tablets in the treatment of schizophrenia in China.
CONCLUSIONS: The aripiprazole ODT is associated with more QALYs at lower costs compared with both aripiprazole SOT and olanzapine SOT in treating schizophrenia in China. PMID: 32757968 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - August 13, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Acute Dystonic Reaction to Aripiprazole in an Adolescent Boy
Journal of Child and Adolescent Psychopharmacology, Ahead of Print. (Source: Journal of Child and Adolescent Psychopharmacology)
Source: Journal of Child and Adolescent Psychopharmacology - August 10, 2020 Category: Pediatrics Authors: Nadina Abdullayeva Raul Poulsen Barbara J. Coffey Source Type: research

[Establishment of a Novel Method to Evaluate Water Permeation Rates by Combining the Dynamic Contact Angle and Thermographic Approach: Significance of Disintegration Properties of Orally Disintegrating Tablets].
Abstract The purpose of the present study was to establish a novel method to evaluate water penetration rates by combining the local dynamic contact angle and thermographic approach to characterize water conduction properties in orally disintegrating (OD) tablets. The OD tablet tester OD-mate was used to measure the disintegration times of OD tablets. Other formulation characteristics, such as tablet hardness and friability, were evaluated. By examining three formulation characteristics, such as the disintegration time, tablet hardness, and friability, of 33 OD tablets for generic drugs, four characteristic OD tab...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - August 5, 2020 Category: Drugs & Pharmacology Authors: Suzuki T, Kurano T, Kanazawa T, Suzuki N Tags: Yakugaku Zasshi Source Type: research

Dissociation in Pharmacokinetic Attenuation Between Central Dopamine D2 Receptor Occupancy and Peripheral Blood Concentration of Antipsychotics: A Systematic Review.
CONCLUSIONS: The findings indicate pharmacokinetic attenuation of antipsychotics was generally slower at the central versus the peripheral level and pose a critical challenge to the current dosing strategy that primarily relies on peripheral pharmacokinetics of antipsychotics. PMID: 32726002 [PubMed - in process] (Source: Journal of Clinical Psychiatry)
Source: Journal of Clinical Psychiatry - July 31, 2020 Category: Psychiatry Tags: J Clin Psychiatry Source Type: research

Lumateperone (Caplyta) for Schizophrenia
Date: July 27, 2020 Issue #:  1603Summary:  The FDA has approved lumateperone (Caplyta— Intracellular Therapies), an oral second-generation antipsychotic, for once-daily treatment of schizophrenia in adults. It is the 13th second-generation antipsychotic drug to be approved by the FDA for this indication. (Source: The Medical Letter)
Source: The Medical Letter - July 20, 2020 Category: Drugs & Pharmacology Authors: admin Tags: Abilify Abilify MyCite Antipsychotics Aripiprazole Asenapine brexpiprazole Caplyta cariprazine Clozapine Clozaril Geodon iloperadine Invega Latuda lumateperone lurasidone Olanzapine paliperidone Quetiapine Rexulti R Source Type: research

Recent Advances in the Pharmacological Management of Behavioral Disturbances Associated with Autism Spectrum Disorder in Children and Adolescents
AbstractAutism spectrum disorder (ASD) is a heterogeneous neuropsychiatric condition affecting an estimated one in 36 children. Youth with ASD may have severe behavioral disturbances including irritability, aggression, and hyperactivity. Currently, there are only two medications (risperidone and aripiprazole) approved by the US Food and Drug Administration (FDA) for the treatment of irritability associated with ASD. Pharmacologic treatments are commonly used to target ASD-associated symptoms including irritability, mood lability, anxiety, and hyperactivity. However, evidence for the efficacy of many commonly used treatment...
Source: Pediatric Drugs - July 19, 2020 Category: Pediatrics Source Type: research

Recent Advances in the Pharmacological Management of Behavioral Disturbances Associated with Autism Spectrum Disorder in Children and Adolescents.
Abstract Autism spectrum disorder (ASD) is a heterogeneous neuropsychiatric condition affecting an estimated one in 36 children. Youth with ASD may have severe behavioral disturbances including irritability, aggression, and hyperactivity. Currently, there are only two medications (risperidone and aripiprazole) approved by the US Food and Drug Administration (FDA) for the treatment of irritability associated with ASD. Pharmacologic treatments are commonly used to target ASD-associated symptoms including irritability, mood lability, anxiety, and hyperactivity. However, evidence for the efficacy of many commonly used...
Source: Paediatric Drugs - July 19, 2020 Category: Pediatrics Authors: Lamy M, Pedapati EV, Dominick KL, Wink LK, Erickson CA Tags: Paediatr Drugs Source Type: research

Second Generation Antipsychotics Monotherapy as Maintenance Treatment for Bipolar Disorder: a Systematic Review of Long-Term Studies
This study is aimed towards a systematic review of their efficacy when used as monotherapy in order to prevent relapses in the long term treatment. Publications about this subject were identified after a thorough bibliographic research in Medline, The Cochrane Library and Web of Science, employing the PICO method for the creation of a database search strategy and carrying out a critical read and analysis of the found evidence. 14 studies were found which informed about the results of randomized and controlled clinical trials (RCT) about the efficacy of these SGA in monotherapy for BD, when it comes to prevention of relapse...
Source: Psychiatric Quarterly - July 9, 2020 Category: Psychiatry Source Type: research

Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study
ConclusionsAL 1064  mg q8wk provided continuous exposure to aripiprazole throughout the 8-week dosing interval and had a safety profile consistent with the 4- and 6-week regimens. These findings were used to support FDA approval of the 1064-mg dose administered every 2 months.RegistrationClinicaltrials.gov: NCT02320032 (Source: CNS Drugs)
Source: CNS Drugs - July 2, 2020 Category: Neurology Source Type: research

Effect of amisulpride, olanzapine, quetiapine, and aripiprazole single administration on c-Fos expression in vasopressinergic and oxytocinergic neurons of the rat hypothalamic supraoptic nucleus.
Authors: Kiss A, Osacka J Abstract OBJECTIVE: The goal of this study was to reveal the impact of four types of atypical antipsychotics including amisulpride (AMI), olanzapine (OLA), quetiapine (QUE), and aripiprazole (ARI), with different receptor-affinity profile and dissociation constant, on the activity of hypothalamic supraoptic nucleus (SON) vasopressinergic and oxytocinergic neurons. METHODS: Male Sprague Dawley rats received a single injection of vehicle (VEH) (0.1 ml/100g), AMI (20 mg/kg), OLA (5 mg/kg), QUE (15 mg/kg/) or ARI (10 mg/kg). Ninety min after treatment, the animals were fixed by transcardia...
Source: Endocrine Regulations - July 2, 2020 Category: Endocrinology Tags: Endocr Regul Source Type: research

c-Fos and FosB/ ΔFosB colocalizations in selected forebrain structures after olanzapine, amisulpride, aripiprazole, and quetiapine single administration in rats preconditioned by two different mild stressors sequences.
CONCLUSION: The present findings indicate that ΔFosB and c-Fos colocalizations occurred in each of the three areas investigated, i.e. seVL, stDL, and shell, in both HDL and CMS preconditioned rats, whereas the parallel occurrence of free c-Fos as well as c-Fos colocalized with ΔFosB might speak out for a possible involvement of the c-Fos activated by antipsychotics applied in dual, i.e. short- and long-lasting, functions. PMID: 32597143 [PubMed - in process] (Source: Endocrine Regulations)
Source: Endocrine Regulations - July 2, 2020 Category: Endocrinology Tags: Endocr Regul Source Type: research

Weight and body mass index increase in children and adolescents exposed to antipsychotic drugs in non-interventional settings: a meta-analysis and meta-regression
AbstractAntipsychotics increase weight, BMI and waist size, particularly in pediatric patients. Switching antipsychotics is common practice, thus defining the risk for each antipsychotic in real-life settings can be important for clinical guidance. We conducted a meta-analysis on antipsychotic-related changes in body measures in pediatric observational studies. Of 934 publications found on PubMed, we analyzed 38, including nine treatment arms: no treatment, mixed antipsychotic treatment, first-generation antipsychotics, aripiprazole, clozapine, olanzapine, quetiapine, risperidone and ziprasidone. Changes in weight, BMI, BM...
Source: European Child and Adolescent Psychiatry - July 1, 2020 Category: Psychiatry Source Type: research

Impact of Concurrent Posttraumatic Stress Disorder on Outcomes of Antipsychotic Augmentation for Major Depressive Disorder With a Prior Failed Treatment: VAST-D Randomized Clinical Trial.
CONCLUSIONS: Although PTSD was associated with poorer overall outcomes, the presence of concurrent PTSD among Veterans in this trial did not affect the comparative effectiveness of medications on response, remission, or relapse after initial remission. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01421342. PMID: 32603560 [PubMed - as supplied by publisher] (Source: Journal of Clinical Psychiatry)
Source: Journal of Clinical Psychiatry - July 1, 2020 Category: Psychiatry Tags: J Clin Psychiatry Source Type: research

Low-dose Aripiprazole Induced Enuresis Continuum in a Child
In this report, we present the case of a 9-year-old boy who developed enuresis continuum after the initiation of a low dose of aripiprazole and describe his rapid improvement when administration of the drug was ended. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - July 1, 2020 Category: Neurology Tags: Case Reports Source Type: research

Treatment of Isolated Cataplexy With Low-dose Aripiprazole in an Adolescent Patient
Conclusions In this case report, we present an adolescent girl with IC that is successfully treated with aripiprazole, an antipsychotic. This case report suggests that aripiprazole may be safely used in some adolescents who diagnosed with IC. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - July 1, 2020 Category: Neurology Tags: Case Reports Source Type: research

Antidepressant Augmentation: A Review of the Literature and a Review of the Pharmacoeconomic Considerations
Purpose Antidepressant augmentation strategies for treatment-resistant depression (TRD) are discussed here with an analysis of patient out-of-pocket costs for various medications. The choice of agent ranges from newer atypical antipsychotics (aripiprazole, brexpiprazole, quetiapine) to older agents including buspirone, liothyronine (T3), and lithium. We sought to better understand the differences among these agents to aid in clinical decision making. Methods We conducted a focused review of the support for each of the aforementioned agents in antidepressant augmentation. We then compared the approximate out-of-pocket ...
Source: Journal of Clinical Psychopharmacology - July 1, 2020 Category: Psychiatry Tags: Brief Reports Source Type: research

Adjunct Aripiprazole for Obsessive-Compulsive Symptoms Associated With Second-Generation Antipsychotics in 2 Patients With Schizophrenia: Anti-obsessional Efficacy of Partial Agonism
No abstract available (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - July 1, 2020 Category: Psychiatry Tags: Letters to the Editors — Case Reports Source Type: research

Aripiprazole Elevated the Thyroid-Stimulating Hormone Level and is Associated With Hyperprolactinemia
No abstract available (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - July 1, 2020 Category: Psychiatry Tags: Letters to the Editors — Case Reports Source Type: research

Variability in Price of Generic Antipsychotic Medications at Community Pharmacies.
CONCLUSIONS: This report is the first on pharmacy-level variability in the costs of generic antipsychotic treatment options for schizophrenia. Appreciable differences were found in the costs of generic antipsychotics. Understanding variability in antipsychotic pricing may be important for providers serving uninsured patients. PMID: 32576120 [PubMed - as supplied by publisher] (Source: Psychiatric Services)
Source: Psychiatric Services - June 26, 2020 Category: Psychiatry Tags: Psychiatr Serv Source Type: research

Price of Antipsychotics Varies Significantly Between Pharmacies, Study Finds
The price of antipsychotic medications varies significantly between pharmacies, sometimes by differences of over $1,000, according to astudy published inPsychiatric Services in Advance.Carrie R. Kriz, M.S., Leigh Anne Nelson, Pharm.D., B.C.P.P., and colleagues from the University of Missouri-Kansas City collected data by calling 281 pharmacies in the Kansas City area and requesting the cash price of a 30-day supply of six generically available antipsychotic medications. Each call included requests for the cash price of two medications at the specific strength and number of doses to “mimic a patient’s interactio...
Source: Psychiatr News - June 25, 2020 Category: Psychiatry Tags: antipsychotics aripiprazole Carrie Kriz haloperidol Leigh Anne Nelson olanzapine Psychiatric Services in Advance quetiapine risperidone ziprasidone Source Type: research

Symptom Dimension of Interest-Activity Indicates Need for Aripiprazole Augmentation of Escitalopram in Major Depressive Disorder: A CAN-BIND-1 Report.
Authors: Uher R, Frey BN, Quilty LC, Rotzinger S, Blier P, Foster JA, Müller DJ, Ravindran AV, Soares CN, Turecki G, Parikh SV, Milev R, MacQueen G, Lam RW, Kennedy SH, CAN-BIND Investigator Team Abstract OBJECTIVE: Differential predictors of response to alternative treatment options are needed to improve the outcomes in major depressive disorder. The symptom dimension comprising loss of interest and reduced activity has been reported as a predictor of poor outcome of treatment with antidepressants. We hypothesized that augmentation with partial dopamine agonist aripiprazole will be effective for individuals w...
Source: Journal of Clinical Psychiatry - June 21, 2020 Category: Psychiatry Tags: J Clin Psychiatry Source Type: research